A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

July 2, 2025

Study Completion Date

September 30, 2025

Conditions
Lupus Nephritis
Interventions
BIOLOGICAL

efgartigimod IV

Intravenous (IV) infusion of efgartigimod

OTHER

Placebo

Intravenous (IV) infusion of placebo

Trial Locations (31)

100191

Peking University Third Hospital, Beijing

310058

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

330006

Jiangxi Provincial People's Hospital, Nanchang

522091

Jieyang People's Hospital, Jieyang

Unknown

Peking University People's Hospital, Beijing

Hunan Provincial People's Hospital, Changsha

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Fujian Medical University Union Hospital, Fujian

Guangdong Provincial People's Hospital, Guangzhou

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

The First Affiliated Hospital,Sun Yat-sen University, Guanzhou

The First Affiliated Hospital, Zhejiang University, Hangzhou

First Affiliated Hospital of University of South China, Hengyang

The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huainan

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan

Affiliated Hospital of Jining Medical University, Jining

Liu Zhou Works Hospital, Liuzhou

The First Affiliated Hospital of Nanchang University, Nanchang

Jiangsu Province Hospital, Nanjing

Zhongda Hospital Southeast University, Nanjing

The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning

Huashan Hospital Fudan University, Shanghai

ShengJing Hospital of China Medical University, Shenyang

Shenzhen People's Hospital, Shenzhen

The First Hospital of Hebei Medical University, Shijia Zhuang

The Second Hospital of Tianjin Medical University, Tianjin

Renmin Hospital of Wuhan University, Wuhan

Wuxi People's Hospital, Wuxi

Shaanxi Provincial Hospital of Chinese Medicine, Xi'an

The First Affiliated Hospital of Xiamen University, Xiamen

Henan Provincial People's Hospital, Zhengzhou

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY

lead

argenx

INDUSTRY

NCT05810948 - A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) | Biotech Hunter | Biotech Hunter